Journal for ImmunoTherapy of Cancer

Universal off-the-shelf combination immunotherapy using oncolytic viruses to redirect T cell engagers to target solid tumors.

IL-12-producing cytokine factories induce precursor exhausted T cells and elimination of primary and metastatic tumors.

HPV16 E6 and E7 expressing cancer cells suppress the antitumor immune response by upregulating KLF2-mediated IL-23 expression in macrophages.

Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy.

B7-H3 CAR-T cell therapy combined with irradiation is effective in targeting bulk and radiation-resistant chordoma cancer cells.

Phosphatidylserine as a tumor target for CAR-T cell therapy.

ANV600 is a novel PD-1 targeted IL-2Rβγ agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy.

High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapy.

Macrophage sensitivity to bexmarilimab-induced reprogramming is shaped by the tumor microenvironment.

Progesterone receptor-dependent downregulation of MHC class I promotes tumor immune evasion and growth in breast cancer.

孕激素受体依赖性MHC I类分子下调促进乳腺癌肿瘤的免疫逃逸和生长